M&A Deal Summary |
|
|---|---|
| Date | 2022-03-24 |
| Target | APIRx Pharmaceutical USA |
| Sector | Life Science |
| Buyer(s) | Incannex Healthcare |
| Deal Type | Add-on Acquisition |
| Deal Value | 93M USD |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 9 |
| Revenue | 1M AUD (2021) |
Incannex Healthcare is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of anxiety disorders, obstructive sleep apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease. Incannex Healthcare is based in Sydney, Australia.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
